Table 2. mRNA splicing-related genes SNPs and lung cancer risk in the TRICL¹ Consortium with FDR corrected P ≤ 0.05.

ID	SNP	Chr: Position2	GENE	Allele3	EAF4	Q5	I2 5	Effects6	OR (95% CI)7	P7	FDR8
1	rs115420460	6: 30618906	DHX16	A/G	0.11	0.67	0.00	++++++	1.18 (1.12–1.25)	3.93E-09	<0.0001
2	rs114312980	6: 31768799	LSM2	A/C	0.11	0.23	26.77	++++++	1.20 (1.12–1.29)	2.19E-07	0.0007
3	rs115489726	6: 31766660	LSM2	C/T	0.11	0.24	25.69	++++++	1.20 (1.12–1.29)	2.54E-07	0.0007
4	rs115801685	6: 31772093	LSM2	C/A	0.11	0.23	27.36	++++++	1.20 (1.12–1.29)	2.61E-07	0.0007
5	rs114637560	6: 31765864	LSM2	T/A	0.15	0.27	22.42	+−++++	1.14 (1.07–1.21)	3.04E-07	0.0007
6	rs115834633	6: 31765984	LSM2	G/A	0.11	0.20	30.79	++++++	1.20 (1.12–1.30)	5.75E-07	0.0011
7	rs116165844	20: 62610556	PRPF6	G/T	0.13	0.89	0.00	−−−−−−	0.89 (0.85–0.94)	1.62E-05	0.0197
8	rs8126213	20: 62611478	PRPF6	G/A	0.13	0.89	0.00	−−−−−−	0.89 (0.85–0.94)	1.64E-05	0.0197
9	rs147176547	20: 62613001	PRPF6	C/G	0.14	0.98	0.00	−−−−−−	0.90 (0.85–0.94)	1.65E-05	0.0197
10	rs112219537	20: 62620029	PRPF6	G/A	0.13	0.96	0.00	−−−−−−	0.90 (0.85–0.94)	2.37E-05	0.0237
11	rs113450630	20: 62623703	PRPF6	C/T	0.14	0.98	0.00	−−−−−−	0.90 (0.85–0.94)	1.93E-05	0.021
12	rs75100087	20: 62636139	PRPF6	C/T	0.14	0.97	0.00	−−−−−−	0.89 (0.85–0.94)	6.83E-06	0.0117

¹TRICL: GWASs datasets combined by six GWASs of ICR, MDACC, IARC, NCI, Toronto and GLC.

²Based on NCBI build 37 of the human genome.

³Reference allele/effect allele.

⁴EAF, effect allele frequency.

⁵Fixed-effects models were used when no heterogeneity was found between studies (Q > 0.10 and I² < 25.0); otherwise, random-effects models were used.

⁶+ means positive association, and − means negative association.

⁷Meta-analysis of additive results from six lung cancer GWASs.

⁸FDR, false discovery rate.